This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
That reframing is the whole thing. The facts I already had.
TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
Orforglipron phase 2: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
Reframing orforglipron phase 2 slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
Adding what did not work for me on orforglipron phase 2, since the failures never get written up and they are half the useful information.
This follows post #65 rather than contradicting it.
The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
The honest answer is that it depends, and here is what it depends on.
What I would check first on orforglipron phase 2 is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
I came in to disagree and I am leaving without a disagreement.
Trying to state the orforglipron phase 2 position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Where I part company with post #71, and it is a narrow parting.
Bringing the previous paper on the same question makes the session much better and doubles the preparation. Worth doing every third session rather than every one.
I am aware this is the third time this month I have made this point.
Orforglipron phase 2 is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.
What I would tell a new member reading about orforglipron phase 2 for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
On post #74 — agreed on the reasoning, with one qualification.
Distinguishing three things in the orforglipron phase 2 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.
The general answer and the answer for your case may diverge here.
The claim about orforglipron phase 2 upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
I had written a reply contradicting post #79 and deleted it. Here is what survived.
Orforglipron phase 2 has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Confirming post #83 from a second method, which matters more than confirming it from a second person.
People arriving without having read it should be welcome and should say so, because a question from someone who has not read it frequently exposes an assumption everyone else made.
Happy to expand any of that if it is the useful part.
Two sentences on orforglipron phase 2 and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
I have seen it go both ways, which is why I hedge.
Narrowing post #87, because the general version has more than one answer.
Offering a way to settle orforglipron phase 2 rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.